BACKGROUND AND PURPOSE: Spinal muscular atrophy, a genetic disease resulting in
loss of motor function, presents from in utero to adulthood. Depending on progression and …

Background Spinal muscular atrophy (SMA) is an autosomal-recessive neuromuscular
disorder resulting in progressive muscle weakness. In December 2016, the US Food and …

Background Nusinersen, the only treatment approved by the United States Food and Drug
Administration for spinal muscular atrophy (SMA), is delivered intrathecally. Many children …

The main purpose of this article is to assess the safety and efficacy of transforaminal lumbar
puncture for the injection of nusinersen (Spinraza) in patients with extensive spinal fusion …

Background and purpose The purpose was to investigate our centre's experience on
computed‐tomography‐guided (CT‐guided), transforaminal, intrathecal administration of …

Spinal deformities and surgical correction of scoliosis can make intrathecal delivery of
nusinersen very challenging. We aim to evaluate the feasibility and safety of intrathecal …

Background Nusinersen is the only approved treatment for all spinal muscular atrophy
(SMA) subtypes and is delivered intrathecally. Distorted spinal anatomy and instrumentation …

PURPOSE Nusinersen is a drug approved in December 2016 for treatment of spinal
muscular atrophy (SMA). We want to share our initial experience with image-guided, non …

BACKGROUND: Spinal muscular atrophy is a progressive neurodegenerative disorder that
can be treated with intrathecal antisense oligonucleotide therapy (nusinersen). However …

Background The treatment of spinal muscular atrophy (SMA) with nusinersen requires
intrathecal medication administration, which can be challenging in individuals with …